Word

PROFERO

Status

Dead

Status Code

606

Status Date

Monday, August 15, 2022

Serial Number

88000887

Mark Type

4000

Filing Date

Thursday, June 14, 2018

Published for Opposition

Tuesday, May 14, 2019

Abandoned Date

Monday, August 15, 2022

Trademark Owner History

The Translational Genomics Research Institute - Owner At Publication

Classifications

5 Testing kits comprised of medical diagnostic reagents and assays that test for the presence of certain genetic properties; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for the analysis of genetic material; Preparations for detecting changes in genes and gene expressions for medical purposes; Chemical reagents for medical analysis; Chemical preparation for use in medical analysis, particularly DNA analysis; Pharmaceutical preparations for diagnosis and for identifying and characterizing genetic abnormalities, tracking the progress of disease and measuring the effectiveness of therapies; Genetic identity tests comprises of reagents for medical purposes; Clinical diagnostic preparations for medical use

1 Chemical test kits for genetic testing for laboratory or research use; Assays and reagents for use in genetic research; Diagnostic preparations for scientific or research use; Nucleic acid isolation and purification kit consisting primarily of reagents for scientific research purposes; Reagents for scientific or medical research use; Clinical diagnostic preparations for clinical or medical laboratory use

44 Medical diagnostic services in the field of molecular science, comparative genome analysis, nucleic acid arrays and screening of nucleic acids; Medical testing, analysis, and evaluation services for medical or diagnostic purposes for providing healthcare information; Providing health care information featuring information resulting from genomic research, testing, analysis, and evaluation; Diagnosis and treatment of medical conditions, namely, of cognitive, neurological, and brain-related conditions; Providing healthcare information; Providing information in the field of disease prevention, screening, diagnosis, and treatment for medical diagnostic and treatment purposes; Medical testing services for diagnostic or treatment purposes in the medical field; Proteogenomic profiling for diagnostic or treatment purposes of cognitive, neurological, and brain-related conditions; Identification of target molecules for disease treatment, namely, treatments of cognitive, neurological, and brain-related conditions

42 Laboratory diagnostic services in the field of molecular science, comparative genome analysis, nucleic acid arrays and screening of nucleic acids; Medical and scientific research in the field of genetic testing and diagnosis and treatment of medical conditions; Development of tests and laboratory testing in the field of genetics and human disease; Scientific research consulting in the field of genetics, genomics, nucleic acid sequencing, and bioinformatics; Consulting services in the field of pharmaceutical research and development and laboratory testing; Genetic research, development and testing services; Genomic research, development and testing services for scientific research purposes; Nucleic acid collection, testing and analysis services for scientific research purposes; Genetic testing for scientific diagnostic research purposes; Genomic testing for scientific diagnostic research purposes; Medical and scientific research, development and consulting in the field of neurology; Medical and scientific research in the field of genetics and genetic engineering; Medical and scientific research and consulting in the fields of genomics and generation sequencing; Medical and scientific research in the field of disease treatment and diagnosis; Medical and scientific research relating to the design and development of treatment therapies; Data collection for research purposes, namely, the collection, testing and research of patient molecular and/or genomic data; Scientific clinical studies, namely, conducting clinical trials for others; Retrieval and correlation of genomic data for research or analysis purposes; Conducting clinical and pre-clinical trials; Targeted pharmaceutical drug development services; Genotyping services for research or analysis purposes; Gene screening for research or analysis purposes; Gene isolation and gene expression analysis for scientific and medical research purposes; Gene mapping; Gene analysis and biomarker discovery for scientific research and medical purposes; Research and development of identification and treatment methods for hereditary factors leading to disease; Nucleic acid-sequencing for scientific research purposes

The English translation of "PROFERO" in the mark is "DELAY".

Trademark Events

Aug 15, 2022

Abandonment Notice E-Mailed - No Use Statement Filed

Aug 15, 2022

Abandonment - No Use Statement Filed

Jan 13, 2022

Notice Of Approval Of Extension Request E-Mailed

Jan 12, 2022

Sou Extension 5 Granted

Jan 5, 2022

Sou Extension 5 Filed

Jan 12, 2022

Case Assigned To Intent To Use Paralegal

Jan 5, 2022

Teas Extension Received

Jul 6, 2021

Notice Of Approval Of Extension Request E-Mailed

Jul 2, 2021

Sou Extension 4 Granted

Jul 2, 2021

Sou Extension 4 Filed

Jul 2, 2021

Teas Extension Received

Dec 24, 2020

Notice Of Approval Of Extension Request E-Mailed

Dec 22, 2020

Sou Extension 3 Granted

Dec 22, 2020

Sou Extension 3 Filed

Dec 22, 2020

Teas Extension Received

Jul 3, 2020

Notice Of Approval Of Extension Request E-Mailed

Jul 1, 2020

Sou Extension 2 Granted

Jul 1, 2020

Sou Extension 2 Filed

Jul 1, 2020

Teas Extension Received

Dec 18, 2019

Notice Of Approval Of Extension Request E-Mailed

Dec 16, 2019

Sou Extension 1 Granted

Dec 16, 2019

Sou Extension 1 Filed

Dec 16, 2019

Teas Extension Received

Jul 9, 2019

Noa E-Mailed - Sou Required From Applicant

May 14, 2019

Official Gazette Publication Confirmation E-Mailed

May 14, 2019

Published For Opposition

Apr 24, 2019

Notification Of Notice Of Publication E-Mailed

Apr 1, 2019

Approved For Pub - Principal Register

Mar 13, 2019

Teas/Email Correspondence Entered

Mar 13, 2019

Correspondence Received In Law Office

Mar 11, 2019

Assigned To Lie

Mar 8, 2019

Teas Response To Office Action Received

Sep 10, 2018

Notification Of Non-Final Action E-Mailed

Sep 10, 2018

Non-Final Action E-Mailed

Sep 10, 2018

Non-Final Action Written

Sep 4, 2018

Assigned To Examiner

Jun 20, 2018

New Application Office Supplied Data Entered In Tram

Jun 18, 2018

New Application Entered In Tram